JP2022510436A - アルストレーム症候群の治療における２－（３－ペンチルフェニル）酢酸ナトリウムの使用 - Google Patents

アルストレーム症候群の治療における２－（３－ペンチルフェニル）酢酸ナトリウムの使用 Download PDF

Info

Publication number
JP2022510436A
JP2022510436A JP2021531937A JP2021531937A JP2022510436A JP 2022510436 A JP2022510436 A JP 2022510436A JP 2021531937 A JP2021531937 A JP 2021531937A JP 2021531937 A JP2021531937 A JP 2021531937A JP 2022510436 A JP2022510436 A JP 2022510436A
Authority
JP
Japan
Prior art keywords
pentylphenyl
acetate
use according
pharmaceutical
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510436A5 (https=
Inventor
ギャニオン，リン
ローラン，ピエール
チェザリ，フランク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal Biosciences Ltd
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Publication of JP2022510436A publication Critical patent/JP2022510436A/ja
Publication of JP2022510436A5 publication Critical patent/JP2022510436A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021531937A 2018-12-05 2019-12-05 アルストレーム症候群の治療における２－（３－ペンチルフェニル）酢酸ナトリウムの使用 Pending JP2022510436A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775849P 2018-12-05 2018-12-05
US62/775,849 2018-12-05
PCT/CA2019/051753 WO2020113340A1 (en) 2018-12-05 2019-12-05 Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome

Publications (2)

Publication Number Publication Date
JP2022510436A true JP2022510436A (ja) 2022-01-26
JP2022510436A5 JP2022510436A5 (https=) 2022-12-08

Family

ID=70973699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531937A Pending JP2022510436A (ja) 2018-12-05 2019-12-05 アルストレーム症候群の治療における２－（３－ペンチルフェニル）酢酸ナトリウムの使用

Country Status (6)

Country Link
US (1) US20220016060A1 (https=)
EP (1) EP3890717A4 (https=)
JP (1) JP2022510436A (https=)
AU (1) AU2019393347A1 (https=)
CA (1) CA3121830A1 (https=)
WO (1) WO2020113340A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761061A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
EA022445B1 (ru) * 2009-05-04 2016-01-29 Прометик Байосайенсиз Инк. Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BMC ENDOCRINE DISORDERS, vol. Vol.18:18, JPN6023046142, November 2018 (2018-11-01), pages 1 - 10, ISSN: 0005338495 *
HEPATOLOGY, vol. VOl.68, Suppl.1, JPN6023046143, October 2018 (2018-10-01), pages 990 - 1737, ISSN: 0005338494 *

Also Published As

Publication number Publication date
WO2020113340A1 (en) 2020-06-11
CA3121830A1 (en) 2020-06-11
EP3890717A1 (en) 2021-10-13
US20220016060A1 (en) 2022-01-20
EP3890717A4 (en) 2022-08-24
AU2019393347A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
US10772865B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
Baker et al. Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization
BRPI1008560B1 (pt) Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
TWI900606B (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
Brown et al. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
JP2013523681A (ja) Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
JP2024523945A (ja) 血糖値の管理方法ならびに糖尿病及び関連状態の治療
US20250262279A1 (en) Dose regimen for long-acting glp1/glucagon receptor agonists
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
WO2020039394A1 (en) New drug combinations
JP2020524176A (ja) 伸長ヌクレオチド反復を含有する遺伝子の有害活性の低減のための化合物
Chen et al. Uncontrolled blood pressure as an independent risk factor of early impaired left ventricular systolic function in treated hypertension
JP5800368B2 (ja) 非アルコール性脂肪性肝炎の予防及び／又は治療剤
US20250339432A1 (en) Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
JP2022510436A (ja) アルストレーム症候群の治療における２－（３－ペンチルフェニル）酢酸ナトリウムの使用
US20230055657A1 (en) Combination treatment of liver diseases using integrin inhibitors
WO2012163088A2 (zh) 肾病和心脏病的治疗药物及其用途
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
EP3199183A1 (en) Renal imaging agent
WO2017217071A1 (ja) セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤
Patil et al. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis
JP2011519877A (ja) インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物
Ahmed EFFECTS OF TRIMETAZIDINE IN THE TREATMENT OF STABLE ANGINA
Felker et al. Worsening Renal Function in Acute Heart Failure: Change in Blood Pressure and Effects of Relaxin
Younossi et al. The Effect of Rifaximin on the Health Related Quality of Life (HRQL) in Patients With Cirrhosis and Recurrent Hepatic Encephalopathy (HE)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240604